Acthar Gel versus standard of care for adults with proteinuria in nephrotic syndrome due to focal segmental glomerulosclerosis: cost-per-response analysis from the US healthcare perspective

Aim: Proteinuria poses a significant challenge in focal segmental glomerulosclerosis (FSGS), particularly when resistant to standard treatments. Acthar R Gel, a Food and Drug Administration (FDA)-approved treatment, may be a potential option for proteinuria in nephrotic syndrome (NS) due to FSGS,...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Jas Bindra, Ishveen Chopra, Kyle Hayes, John Niewoehner, Mary Panaccio, George J Wan
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Becaris Publishing Limited 2026-01-01
Ráidu:	Journal of Comparative Effectiveness Research
Fáttát:	acthar gel cost-per-response focal segmental glomerulosclerosis nephrotic syndrome proteinuria repository corticotropin injection
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!